Viatris Earnings Call Transcripts
Fiscal Year 2026
-
A focused transformation has positioned the company for sustainable growth, targeting 5%-6% revenue and 7%-8% EBITDA growth by 2030, with over $11B in capital for deployment. Key drivers include a robust pipeline, disciplined business development, and operational efficiencies.
-
Management highlighted strong 2025 execution, robust pipeline progress, and a strategic shift toward sustainable growth starting in 2026. Key launches, business development, and an enterprise-wide review are set to drive mid-single digit revenue growth and operational efficiency.
Fiscal Year 2025
-
2025 saw 2% revenue growth and strong pipeline progress, with $14.3B in revenue and $4.2B Adjusted EBITDA. Strategic review identified $650M in cost savings, supporting 2% growth guidance for 2026 and multiple product launches. Over $1B was returned to shareholders.
-
Management outlined a strategy focused on reinforcing the base business, driving innovation, and optimizing costs for sustainable growth. Key pipeline assets, including fast-acting meloxicam and late-stage candidates selatogrel and cenerimod, are expected to drive future revenue, with launches and pivotal data readouts anticipated next year.
-
Management outlined a balanced capital allocation strategy, prioritizing branded asset acquisitions and shareholder returns. Key pipeline assets cenerimod and selatogrel are advancing in late-stage trials, while fast-acting meloxicam and MR-141 offer new growth opportunities. An enterprise-wide review targets long-term efficiency and savings.
-
Strong commercial execution and pipeline progress in 2025 set the stage for sustained growth in 2026. Major cost savings from an enterprise review will mostly benefit the bottom line, while new product launches and a balanced capital allocation strategy support revenue expansion.
-
Momentum continues with 2-3% operational revenue growth expected into 2026, supported by strong new product launches and robust performance in China and emerging markets. Strategic review aims for sustainable cost savings, while capital allocation remains balanced between business development and shareholder returns.
-
Q3 2025 saw solid operational growth, strong free cash flow, and increased capital returns. Strategic review and pipeline progress, including fast-acting meloxicam and new CNS assets, position the company for sustained growth. Indore remediation and market dynamics remain key watchpoints.
-
Q2 2025 saw 3% operational revenue growth (ex-indoor), strong pipeline progress, and robust performance in Europe and Greater China. Guidance for 2025 is reaffirmed, with expectations to hit the top half of revenue and EPS ranges, and no material tariff impact anticipated.
-
Strong base business and pipeline progress underpin a strategy focused on sustainable growth, innovation, and operational efficiency. Key assets in pain, cardiology, immunology, and eye care are advancing, while capital allocation balances shareholder returns and business development.
-
Execution remains the central theme, with strong operational growth, robust cash flow, and a reaffirmed outlook despite Indore-related headwinds. New product launches and pipeline progress, especially in non-opioid pain management, are set to drive second-half performance.
-
Streamlined operations and divestitures have set the stage for a focus on innovative, durable brands and global growth. Near-term growth is expected from new product launches, with a strong R&D pipeline and a balanced capital deployment strategy.
-
Q1 2025 results met expectations with $3.3B revenue, strong pipeline progress, and $450M capital returned to shareholders. Indore facility impact was managed, guidance reaffirmed, and key product launches are on track for the second half.
-
Strong fundamentals and cash flow support a balanced capital allocation strategy, despite a reset from the Indore facility's regulatory impact. New product launches and pipeline assets are expected to drive growth from 2026, with ongoing enterprise review and targeted business development.
-
Management highlighted strong 2024 results, including revenue growth, debt reduction, and pipeline expansion. Strategic focus for 2025 is on share repurchases, disciplined business development, and launching key generics and innovative products, with a stable outlook in major markets.
Fiscal Year 2024
-
2024 saw 2% operational revenue growth, strong cash flow, and significant capital returns, but 2025 guidance reflects a $500M revenue and $385M EBITDA hit from Indore facility issues, mainly impacting high-margin products. Remediation is underway, with growth expected to resume in 2026.
-
Management highlighted six quarters of growth, major debt reduction, and a robust pipeline with $450–$600 million in new product revenue expected annually. Geographic and product diversification underpin stability, while disciplined capital allocation and business development aim to accelerate growth into 2025.
-
Operational growth continues with strong new product revenue and robust cash flow, supporting a flexible capital allocation strategy. Innovative pipeline assets are on track for late-decade launches, with a focus on ophthalmology, GI, dermatology, and cardiovascular.
-
Q3 2024 saw continued operational revenue growth, higher adjusted EBITDA and EPS, and strong free cash flow. Debt repayment accelerated, leverage targets are in sight, and capital allocation will focus on shareholder returns and disciplined business development.
-
Q2 2024 saw operational revenue and adjusted EBITDA each grow 2% year-over-year, with all segments posting gains and new product revenue guidance raised to $500–$600 million. The company completed major divestitures, paid down $800 million in debt, and is accelerating its innovative pipeline, positioning for continued growth and strong cash flow.
-
2024 marks a transition year, with divestitures nearly complete and a focus on acquiring late-stage, high-potential assets. Strong cash flow and a diversified global footprint support ongoing product launches and growth, with new assets like cenerimod and selatogrel expected to drive future revenue.
-
The organization has undergone major transformation, executing multiple divestitures and acquisitions, strengthening its balance sheet, and focusing on growth through a robust pipeline in eye care, cardiovascular, and immunology. Financial flexibility and a strong global footprint position it for accelerated growth and shareholder returns in 2025 and beyond.